(Total Views: 118)
Posted On: 06/12/2019 12:31:54 PM
Post# of 44062
$RGBP Regen BioPharma, Inc. Responds To Fake News Release
AN DIEGO , May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Responding to these inquiries the Company reports that it is currently not in any discussions with any other companies regarding a reverse merger.
"This false news release was brought to my attention by a number of people. I have read the news release in question and can state that it is totally untrue," says David Koos , Ph.D., Chairman & CEO of both Regen BioPharma, Inc. "We are focused on our own business model of small molecule immunotherapies for treating cancer and autoimmune disorders."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com .
AN DIEGO , May 8, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP), has received a number of inquiries regarding a potential reverse merger with another biotechnology related company.
Responding to these inquiries the Company reports that it is currently not in any discussions with any other companies regarding a reverse merger.
"This false news release was brought to my attention by a number of people. I have read the news release in question and can state that it is totally untrue," says David Koos , Ph.D., Chairman & CEO of both Regen BioPharma, Inc. "We are focused on our own business model of small molecule immunotherapies for treating cancer and autoimmune disorders."
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com .
(0)
(0)
